Aethlon Medical (NASDAQ:AEMD – Get Free Report) is projected to post its Q2 2027 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($2.91) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2027 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:30 PM ET.
Aethlon Medical (NASDAQ:AEMD – Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The medical equipment provider reported ($4.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.92) by ($0.10). On average, analysts expect Aethlon Medical to post ($5.74) EPS for the current fiscal year and ($0.57) EPS for the next fiscal year.
Aethlon Medical Trading Down 1.9%
Shares of NASDAQ:AEMD opened at $5.69 on Wednesday. The company has a 50 day moving average of $4.59 and a 200-day moving average of $7.72. The firm has a market cap of $4.04 million, a P/E ratio of -0.16 and a beta of 1.27. Aethlon Medical has a twelve month low of $1.41 and a twelve month high of $25.66.
Wall Street Analysts Forecast Growth
Several equities research analysts recently commented on the company. HC Wainwright reissued a “neutral” rating on shares of Aethlon Medical in a report on Friday, September 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a research note on Thursday, October 15th. Finally, Wall Street Zen raised Aethlon Medical to a “sell” rating in a research note on Saturday, October 17th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $1.50.
Get Our Latest Stock Analysis on Aethlon Medical
About Aethlon Medical
Aethlon Medical, Inc is a biotechnology and medical-device company focused on developing extracorporeal blood filtration technologies for life-threatening diseases. The company’s lead product candidate, the Hemopurifier, is designed to selectively remove harmful substances from the bloodstream, including cancer-promoting exosomes and certain viral particles.
The Hemopurifier is intended to be used with standard dialysis or blood-circulation equipment and is being investigated for potential applications in oncology and infectious disease.
Featured Articles
- Five stocks we like better than Aethlon Medical
- High Voltage Returns: Talen Energy Powers the Data Center Rush
- 3 Dividend Increases Above 10%, But Which Offers the Most Income?
- Meta’s $100 Billion AI Financing Plan Has a Catch for Existing Shareholders
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
